Prothena Corporation plc is a US-based clinical company focused on discovering and developing novel therapies to treat life-threatening diseases. Their ongoing clinical trials include Birtamimab, Prasinezumab, PRX004 and PRX005 for the treatment of Amyloidosis, Parkinson's disease, Alzheimer's disease, and Transthyretin amyloidosis. Prothena Corporation also has collaboration and licensing agreements with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. and Bristol-Myers Squibb to develop antibodies.